Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Tavassoli

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Virology Journal|July 27, 2013
Influenza A/Hong Kong/156/1997(H5N1) virus NS1 gene mutations F103L and M106I both increase IFN antagonism, virulence and cytoplasmic localization but differ in binding to RIG-I and CPSF30Samar K Dankar, Elena Miranda, Nicole E Forbes, et al.
Journal of the American Chemical Society|March 19, 2024
Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer CellsAndrew T Ball, Soran Mohammed, Cyrielle Doigneaux, et al.
Chemical Science|August 7, 2018
Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligaseEilidh K Leitch, Nagarajan Elumalai, Maria Fridén-Saxin, et al.
Nature Chemical Biology|March 7, 2018
A lanthipeptide library used to identify a protein-protein interaction inhibitorXiao Yang, Katherine R Lennard, Chang He, et al.
Bioorganic & Medicinal Chemistry|April 26, 2005
Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathwayHeng Cheng, Inkyu Hwang, Youhoon Chong, et al.
Bioorganic & Medicinal Chemistry|September 18, 2003
10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylaseThomas H Marsilje, Michael P Hedrick, Joel Desharnais, et al.
Scientific Reports|June 10, 2017
Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interactionAbigail L Male, Fedor Forafonov, Francesco Cuda, et al.
Chemical Science|August 30, 2018
Fluorescent transmembrane anion transporters: shedding light on anionophoric activity in cellsStuart N Berry, Vanessa Soto-Cerrato, Ethan N W Howe, et al.
Biochemistry|May 21, 2003
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acidYan Zhang, Joel Desharnais, Thomas H Marsilje, et al.
Science Signaling|May 7, 2020
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulatorsCharles N Birts, Arindam Banerjee, Matthew Darley, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Virology Journal|July 27, 2013
Influenza A/Hong Kong/156/1997(H5N1) virus NS1 gene mutations F103L and M106I both increase IFN antagonism, virulence and cytoplasmic localization but differ in binding to RIG-I and CPSF30Samar K Dankar, Elena Miranda, Nicole E Forbes, et al.
Journal of the American Chemical Society|March 19, 2024
Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer CellsAndrew T Ball, Soran Mohammed, Cyrielle Doigneaux, et al.
Chemical Science|August 7, 2018
Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligaseEilidh K Leitch, Nagarajan Elumalai, Maria Fridén-Saxin, et al.
Nature Chemical Biology|March 7, 2018
A lanthipeptide library used to identify a protein-protein interaction inhibitorXiao Yang, Katherine R Lennard, Chang He, et al.
Bioorganic & Medicinal Chemistry|April 26, 2005
Synthesis and biological evaluation of N-[4-[5-(2,4-diamino-6-oxo-1,6-dihydropyrimidin-5-yl)-2-(2,2,2-trifluoroacetyl)pentyl]benzoyl]-L-glutamic acid as a potential inhibitor of GAR Tfase and the de novo purine biosynthetic pathwayHeng Cheng, Inkyu Hwang, Youhoon Chong, et al.
Bioorganic & Medicinal Chemistry|September 18, 2003
10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylaseThomas H Marsilje, Michael P Hedrick, Joel Desharnais, et al.
Scientific Reports|June 10, 2017
Targeting Bacillus anthracis toxicity with a genetically selected inhibitor of the PA/CMG2 protein-protein interactionAbigail L Male, Fedor Forafonov, Francesco Cuda, et al.
Chemical Science|August 30, 2018
Fluorescent transmembrane anion transporters: shedding light on anionophoric activity in cellsStuart N Berry, Vanessa Soto-Cerrato, Ethan N W Howe, et al.
Biochemistry|May 21, 2003
Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acidYan Zhang, Joel Desharnais, Thomas H Marsilje, et al.
Science Signaling|May 7, 2020
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulatorsCharles N Birts, Arindam Banerjee, Matthew Darley, et al.
Pageof 7